 SAN DIEGO, March 25, 2021 GLOBE NEWSWIRE -- Histogen Inc. NASDAQ: HSTO, a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the bodys natural process to repair and maintain healthy biological function has appointed Rochelle Fuhrmann to its Board of Directors and Chairperson of the Audit Committee. In addition, current director Stephen Chang, Ph.D. will be resigning from the Board. 